de Prisco Nicola, Botta Salvatore, Lee Winston, Rezazadeh Sarallah, Chemiakine Alexei, Gennarino Vincenzo A
Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Department of Translational Medical Science, University of Campania Luigi Vanvitelli, Caserta, 81100, Italy.
STAR Protoc. 2022 Mar 15;3(2):101232. doi: 10.1016/j.xpro.2022.101232. eCollection 2022 Jun 17.
Quantifying differences in the amount of protein and mRNA caused by missense mutations in a gene of interest can be challenging, especially when using patient-derived primary cells, which are intrinsically variable. In this protocol, we describe how to culture patient-derived lymphoblast and fibroblast cell lines for later mRNA and protein quantification. We also describe the steps to examine variants of PUM1 in HEK293T cells, but the protocol can be applied to other proteins of interest. For complete details on the use and execution of this protocol, please refer to Gennarino et al. (2018).
量化由感兴趣基因中的错义突变导致的蛋白质和mRNA数量差异可能具有挑战性,尤其是在使用患者来源的原代细胞时,这些细胞本质上具有变异性。在本方案中,我们描述了如何培养患者来源的淋巴母细胞和成纤维细胞系,以便后续进行mRNA和蛋白质定量。我们还描述了在HEK293T细胞中检测PUM1变体的步骤,但该方案可应用于其他感兴趣的蛋白质。有关本方案的使用和执行的完整详细信息,请参考Gennarino等人(2018年)的文献。